Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-20T03:42:52.528Z Has data issue: false hasContentIssue false
  • English
  • Français

Antimicrobial Use Prior to the Acquisition of Multiresistant Bacteria

Published online by Cambridge University Press:  02 January 2015

Matthieu Eveillard ,
Jean-Luc Schmit  and
François Eb
Matthieu Eveillard*
Affiliation:
Department of Bacteriology, Hygiene and Infection Control, Centre Hospitalier Universitaire, Hôpital Nord, Amiens, France
Jean-Luc Schmit
Affiliation:
Department of Infectious Diseases, Centre Hospitalier Universitaire, Hôpital Nord, Amiens, France
François Eb
Affiliation:
Department of Bacteriology, Hygiene and Infection Control, Centre Hospitalier Universitaire, Hôpital Nord, Amiens, France
*
Unité d'Hygiène el de Prévention des Infections Nosocomiales, Centre Hospitalier Universitaire d'Amiens, Hôpital Nord, 80054 Amiens Cedex 1, France
Get access Rights & Permissions [Opens in a new window]

Abstract

We assessed whether patients who acquired methicillin-resistant Staphylococcus aureus (MRSA) had less exposure to antimicrobial agents than did those who acquired Enterobacteriaceae that produced extended-spectrum β-lactamase (ESβL). In a 6-month, prospective study, ESβL carriers had received antimicrobial therapy more often than had MRSA carriers. Amoxicillin-clavulanic acid, fluoroquinolones, and third-generation cephalosporins, especially ceftazidime, had been prescribed more often for ESβL carriers than for MRSA carriers.

Type
Concise Communications
Information
Infection Control & Hospital Epidemiology , Volume 23 , Issue 3 , March 2002 , pp. 155 - 158
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Shlaes, DM, Gerding, DN, John, JF, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol 1997;18:275–291.CrossRefGoogle ScholarPubMed
2.Ayliffe, GAJ. The progressive intercontinental spread of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 1997;24(suppl 1):74–79.CrossRefGoogle ScholarPubMed
3.Meyer, KS, Urban, C, Eagan, JA, Berger, BJ, Rahal, JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993;119:353–358.CrossRefGoogle ScholarPubMed
4.Naumovski, L, Quinn, JP, Miyashiro, D. Outbreak of ceftazidime resistance due to a novel extended-spectrum β-lactamase in isolates from cancer patients. Antimicrob Agents Chemother 1992;36:1991–1996.CrossRefGoogle ScholarPubMed
5.Crowcroft, NS, Ronveaux, O, Monnet, DL, Mertens, R. Methicillin-resistant Staphylococcus aureus and antimicrobial use in Belgian hospitals. Infect Control Hosp Epidemiol 1999;20:31–36.CrossRefGoogle ScholarPubMed
6.Monnet, DL. Methicillin-resistant Staphylococcus aureus and its relationship to antimicrobial use: possible implications for control. Infect Control Hosp Epidemiol 1998;19:552–559.CrossRefGoogle ScholarPubMed
7.Comité de l'Antibiogramme de la Société Française de Microbiologie. Communiqué 1998. Pathol Biol 1998;46:I–XVI.Google Scholar
8.Jarlier, V, Nicolas, MH, Fournier, G, Philippon, A. Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Reviews of Infectious Diseases 1988;10:867–878.CrossRefGoogle ScholarPubMed
9.Bosi, C, Davin-Regli, A, Bornet, C, Mallea, M, Pages, JM, Bollet, C. Most Enterobacter aerogenes strains in France belong to a prevalent clone. J Clin Microbiol 1999;37:2165–2169.CrossRefGoogle ScholarPubMed
10.Pujol, M, Pena, C, Pallares, R, Ariza, J, Ayats, J, Dominguez, MA. Nosocomial Staphylococcus aureus bacteremia among nasal carriers of methicillin-resistant and methicillin-susceptible strains. Am J Med 1996;100:509–516.CrossRefGoogle ScholarPubMed
11.Pechere, JC, Vladoianu, IR. Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model. J Antimicrob Chemother 1992;29:563–573.CrossRefGoogle Scholar
12.Negri, MC, Baquero, F. In vitro selective concentrations of cefepime and ceftazidime for AmpC beta-lactamase hyperproducer Enterobacter cloacae variants. Clinical Microbiology and Infection 1999;5(suppl 1):S25–S28.CrossRefGoogle ScholarPubMed
13.Rice, LB, Eckstein, EC, DeVente, J, Shlaes, M. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis 1996;23:118–124.CrossRefGoogle ScholarPubMed